<DOC>
	<DOCNO>NCT00003892</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness ISIS 5132 treat patient metastatic recurrent ovarian cancer respond previous chemotherapy .</brief_summary>
	<brief_title>ISIS 5132 Treating Patients With Metastatic Recurrent Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy ISIS 5132 evaluate objective response duration response patient recurrent ovarian epithelial cancer . II . Determine tolerability quantitative toxicity ISIS 5132 patient population . OUTLINE : This multicenter study . Patients receive ISIS 5132 IV continuously 21 day . Courses repeat every 28 day . Treatment continue maximum 12 course absence disease progression unacceptable toxicity . Patients document complete response receive additional 2 course . Patients document partial response receive additional 4 course . Patients follow 4 week , every 3 month disease relapse progression . PROJECTED ACCRUAL : A total 15-30 patient accrue study 12-15 month .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>ISIS 5132</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document ovarian epithelial cancer Metastatic and/or locally recurrent disease incurable standard therapy Must receive 1 2 prior regimen chemotherapy At least 1 regimen must contain cisplatin carboplatin Bidimensionally measurable disease Indicator lesion size must follow : At least 450 cm2 CT scan At least 1 cm2 chest xray At least 1 cm2 ( e.g. , nodule ) physical exam No abdominal adenocarcinoma unknown origin No borderline ovarian tumor No tumor know primary fallopian tube peritoneal origin PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 12 week Hematopoietic : Platelet count least 100,000/mm3 Absolute granulocyte count least 1,500/mm3 No know bleed disorder Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) AST le 5 time ULN PT/PTT normal ( except elevate due therapeutic coumadin ) Renal : Creatinine great 2 time ULN Cardiovascular : No significant cardiac dysfunction Neurologic No history significant neurologic disorder No significant psychiatric disorder Other : Not pregnant nursing Fertile patient must use effective contraception At least 5 year since prior malignancy evidence recurrence No serious illness medical condition No active uncontrolled infection No complete bowel obstruction PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy No concurrent cytotoxic therapy Endocrine therapy : Not specify Radiotherapy : Recovered prior radiotherapy At least 4 week since radiotherapy least 20 % bone marrow Surgery : Not specify Other : As least 28 day since prior investigational agent new anticancer therapy No concurrent therapeutic heparin No concurrent investigational therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>